Related Experiment Video
Updated: Feb 6, 2026

Generation of CAR T Cells for Adoptive Therapy in the Context of Glioblastoma Standard of Care
Published on: February 16, 2015
Tumor Antigen Escape from CAR T-cell Therapy
Robbie G Majzner1, Crystal L Mackall2,3,4
1Department of Pediatrics, Stanford University School of Medicine, Stanford, California.
Abstract:
Emerging data from chimeric antigen receptor (CAR) T-cell trials in B-cell malignancies demonstrate that a common mechanism of resistance to this novel class of therapeutics is the emergence of tumors with loss or downregulation of the target antigen. Antigen loss or antigen-low escape is likely to emerge as an even greater barrier to success in solid tumors, which manifest greater heterogeneity in target antigen expression. Potential approaches to overcome this challenge include engineering CAR T cells to achieve multispecificity and to respond to lower levels of target antigen and more efficient induction of natural antitumor immune responses as a result of CAR-induced inflammation. In this article, we review the evidence to date for antigen escape and downregulation and discuss approaches currently under study to overcome these obstacles.Significance: Antigen escape and downregulation have emerged as major issues impacting the durability of CAR T-cell therapy. Here, we explore their incidence and ways to overcome these obstacles in order to improve clinical outcomes. Cancer Discov; 8(10); 1219-26. ©2018 AACR.
Insights
Antigen loss is a key resistance mechanism for CAR T-cell therapy. Strategies to engineer CAR T cells for multispecificity and enhanced immune responses are being explored to overcome this challenge in B-cell malignancies and solid tumors.
Area of Science:
- Immunotherapy
- Oncology
- Cellular Therapy
Background:
- Chimeric antigen receptor (CAR) T-cell therapy shows promise for B-cell malignancies.
- Antigen loss or downregulation is a primary resistance mechanism observed in CAR T-cell trials.
- Solid tumors present greater heterogeneity, potentially exacerbating antigen escape issues.
Purpose of the Study:
- To review evidence of antigen escape and downregulation in CAR T-cell therapy.
- To discuss strategies for overcoming antigen loss as a barrier to CAR T-cell efficacy.
- To explore approaches for improving the durability of CAR T-cell treatment outcomes.
Main Methods:
- Review of emerging data from CAR T-cell trials.
- Analysis of resistance mechanisms, specifically antigen loss and downregulation.
- Exploration of potential engineering strategies for CAR T cells.
Main Results:
- Antigen loss is a common resistance mechanism in B-cell malignancies treated with CAR T cells.
- Antigen heterogeneity in solid tumors suggests antigen escape will be a significant challenge.
- Engineering CAR T cells for multispecificity and enhanced immune responses are potential solutions.
Conclusions:
- Antigen escape and downregulation significantly impact CAR T-cell therapy durability.
- Developing strategies to overcome antigen loss is crucial for improving clinical outcomes.
- Further research into novel CAR T-cell engineering approaches is warranted.
Related Concept Videos
Escape Velocity
To calculate the escape velocity, it is assumed that no energy is lost to any frictional forces. In practice, a satellite...
Antigen Presenting Cells
T cells require the help of antigen-presenting cells (APCs), which process foreign antigens into smaller fragments that can be recognized by T cells. These APCs are highly specialized cells that efficiently internalize antigens...
Escape Velocities of Gases
Gene Therapy
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
Group Therapy

